EU Okays CV Benefit Labeling for Canagliflozin in Diabetes EU Okays CV Benefit Labeling for Canagliflozin in Diabetes

The European label for the SGLT2 inhibitor canagliflozin for type 2 diabetes will now include positive cardiovascular benefit results from the CANVAS trial, while a decision from the US FDA is forthcoming.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news